Navigation Links
Interleukin Genetics Appoints Todd Anthony Walker as Vice President, Marketing
Date:12/8/2008

WALTHAM, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that Todd Anthony Walker has joined the Company as Vice President, Marketing. Mr. Walker will be responsible for all marketing activities for Interleukin Genetics and will be reporting to the Chief Executive Officer, Lewis H. Bender. Mr. Walker brings to the firm extensive marketing experience, as well as 20 years of industry-related experience.

Prior to joining Interleukin Genetics, Mr. Walker was the Worldwide Marketing Director for the Biopatch and OMNEX and synthetic sealants for Johnson & Johnson (JNJ) having worked in the Ethicon Inc., Jansen, Ortho-McNeil and PSGA divisions. Mr. Walker was responsible for developing global marketing strategies, establishing and influencing regional launches for products and building the framework for multigenerational product plans. Prior to joining Johnson & Johnson, Mr. Walker worked as a manager in various capacities with the Procter & Gamble Company.

"We are very pleased to have Todd Walker join Interleukin Genetics as Vice President, Marketing. He brings extensive experience in marketing of pharmaceutical and medical products to the consumer. Todd will have an office in Ada, Michigan, as well as Waltham Massachusetts, and he will spend significant time at our primary customer, Alticor," said Lewis H. Bender Chief Executive Officer at Interleukin Genetics.

Mr. Walker holds a Masters of Business Administration from Duke University's FUQUA School of Business, and a Bachelor's of Science Electrical Engineering Degree from Union College in Schenectady, New York.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Reports Third Quarter 2008 Financial Results
2. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
3. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
4. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
5. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
6. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
7. Interleukin Genetics to Present at 2008 BIO International Convention
8. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
9. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
Breaking Biology News(10 mins):